Sigma-Aldrich Corp

Sigma-Aldrich — J.P. Morgan Healthcare Conference 2014

28 slides from Sigma-Aldrich's conference presentation, Jan 13, 2014

  1. Slide 1: J.P. Morgan Healthcare Conference January 2014

    Slide 1: J.P. Morgan Healthcare Conference January 2014

    J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2014 J.P. MORGAN HEALTHCARE CONFERENCE SIGMA-ALDRICH © 2014 Sigma-Aldrich Co. LLC. All rights reserved.

  2. Slide 2: Cautionary Statements

    Slide 2: Cautionary Statements

    2 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CAUTIONARY STATEMENTS This presentation contains “forward-looking statements” regarding future sales, earnings, return on equity, return on invested capital, cost savings, process improvements, free cash flow, s

  3. Slide 3: Our Purpose: Enabling Science to Improve the Quality of Life

    Slide 3: Our Purpose: Enabling Science to Improve the Quality of Life

    3 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. RESEARCH APPLIED SAFC COMMERCIAL Discovery efforts in life science and material science research Clinical and environmental diagnostics Industrial applications Pharma and electronics manufacturing OUR PURPOSE Th

  4. Slide 4: Constant and Consistent Purpose Has Driven the Company

    Slide 4: Constant and Consistent Purpose Has Driven the Company

    4 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CONSTANT AND CONSISTENT PURPOSE HAS DRIVEN THE COMPANY that will make the world a safer, cleaner, and healthier place 160+ COUNTRIES $2.7B* SALES REVENUE 1.4M INDIVIDUAL CUSTOMERS >215K PRODUCTS & SERVICES SOLUT

  5. Slide 5: Customer Focused, Globally Balanced

    Slide 5: Customer Focused, Globally Balanced

    5 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED, GLOBALLY BALANCED 52% 23% 25% SAFC COMMERCIAL BUSINESS UNIT Life Science Products Life Science Services Hitech APPLIED BUSINESS UNIT Diagnostics and Testing Industrial Applications RESEARCH BUS

  6. Slide 6: 2013 Highlights

    Slide 6: 2013 Highlights

    6 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. 2013 HIGHLIGHTS Realigned into 3 Customer-Facing Business Units *Last twelve months sales ended 9/30/13. HONORED FOR GLOBAL CITIZENSHIP DOW JONES SUSTAINABILITY INDEX, CIVIC 50, CDP GLOBAL 500, CLIMATE DISCLOSUR

  7. Slide 7: Research Business Unit: Addressable Markets

    Slide 7: Research Business Unit: Addressable Markets

    7 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. MISSION: ADDRESSABLE MARKETS: LTM SALES (ENDED 9/30/13): Enabling scientific research to discover and develop new drugs and materials • Markets defined as chemicals, reagents and kits • Fragmented markets, diver

  8. Slide 8: Research Market Trends

    Slide 8: Research Market Trends

    8 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. RESEARCH MARKET TRENDS Large Pharma R&D Consolidation U.S. Academic Funding Constraints Collaborations eCommerce Translational Research Emerging Markets ~5% 52% RESEARCH ~9% US ACADEMICLARGE PHARMA RESEARCH % O

  9. Slide 9: Strong Position in Large Pharma Research

    Slide 9: Strong Position in Large Pharma Research

    9 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. STRONG POSITION IN LARGE PHARMA RESEARCH LARGE STRATEGIC CUSTOMERS SIGMA-ALDRICH PRESENCE 2 LARGEST DISTRIBUTORS A l l B l l C l l D l l E l l F l l G l l l H l l I l l J l l K l l L l l M l l N l l SIGMA-ALDRIC

  10. Slide 10: Sigma-Aldrich.com: #1 in Life Science eCommerce

    Slide 10: Sigma-Aldrich.com: #1 in Life Science eCommerce

    10 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. SIGMA-ALDRICH.COM #1 IN LIFE SCIENCE ECOMMERCE SALES* VISITS ORDERS ~$1B 67M 2.6M Source: coremetrics & BI, Alexa Pro, Normalized to SIAL Coremetrics 30% 36% 34% ASIA PACIFIC EUROPE, MIDDLE EAST, AFRICA AMERIC

  11. Slide 11: Customer Focused Research Sales Gain Traction in 2013

    Slide 11: Customer Focused Research Sales Gain Traction in 2013

    11 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED RESEARCH SALES GAIN TRACTION IN 2013 ACADEMIC PHARMA DEALERS VALUE PROPOSITION Enabling scientists to innovate, conduct and publish quality research through breadth of scientific products and c

  12. Slide 12: Research Organic Sales Growth

    Slide 12: Research Organic Sales Growth

    12 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 RESEARCH ORGANIC SALES GROWTH LONG-TERM EXPECTATIONS Low to Mid Single Digit *Provided on Oct 2013 Q3 conference call (Mid Single Digit) (Low Single Digit) Low Single Digit Mid Single Digit High Single Di

  13. Slide 13: Applied Business Unit: Markets Are Large and Growing

    Slide 13: Applied Business Unit: Markets Are Large and Growing

    13 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. MISSION: LTM SALES (ENDED 9/30/13): Supply customized solutions and critical components and materials to diagnostic companies, testing laboratories and industrial companies APPLIED MARKETS ARE LARGE AND GROWING

  14. Slide 14: Applied Market Segments

    Slide 14: Applied Market Segments

    14 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. APPLIED MARKET SEGMENTS Applied markets are large and growing with solid underlying macroeconomic growth fundamentals Source: Frost & Sullivan, Kalorama; Strategic Directions International Report DIAGNOSTIC MAN

  15. Slide 15: Customer Focused Applied Sales Gaining Traction

    Slide 15: Customer Focused Applied Sales Gaining Traction

    15 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. CUSTOMER FOCUSED APPLIED SALES GAINING TRACTION DIAGNOSTIC & TESTING LABS INDUSTRIAL VALUE PROPOSITION Providing products ranging from raw materials and basic research reagents to components and assays to perfo

  16. Slide 16: Applied Organic Sales Performance

    Slide 16: Applied Organic Sales Performance

    16 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 APPLIED ORGANIC SALES PERFORMANCE LONG-TERM EXPECTATIONS Mid –High Single Digit 2013 Applied organic sales growth guidance* of mid single digit *Provided on Oct 2013 Q3 conference call (Mid Single Digit)

  17. Slide 17: SAFC Commercial Business Unit Overview

    Slide 17: SAFC Commercial Business Unit Overview

    17 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. LTM SALES (ENDED 9/30/13):MISSION: To develop and manufacture products and services solutions for the commercial production of our Pharma, BioPharma and Electronics customers SAFC COMMERCIAL BUSINESS UNIT ~$0.7

  18. Slide 18: SAFC Commercial Value Proposition

    Slide 18: SAFC Commercial Value Proposition

    18 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. VALUE PROPOSITION High quality products and services solutions which are tough to make, difficult to replicate, critical to performance of our customers’ products and processes and represent small portion of th

  19. Slide 19: SAFC Commercial Offerings Enabling Customers to Manufacture

    Slide 19: SAFC Commercial Offerings Enabling Customers to Manufacture

    19 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SAFC COMMERCIAL OFFERINGS ENABLING CUSTOMERS TO MANUFACTURE DRUGS AND MATERIALS BUSINESS UNIT SEGMENTS BUSINESS UNIT INITIATIVES DESCRIPTION 2013 SAFC SALES* CUSTOMER MARKETS Biological Drugs Small Molecule Dru

  20. Slide 20: SAFC Commercial Expansion Activities

    Slide 20: SAFC Commercial Expansion Activities

    20 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SAFC COMMERCIAL EXPANSION ACTIVITIES LIFE SCIENCE PRODUCTS LIFE SCIENCE SERVICES HITECH ELECTRONICS • Expanding dry powder media capacity in Scotland • Expanding high potency API capacity in Wisconsin • Expandi

  21. Slide 21: SAFC Commercial Organic Sales Performance

    Slide 21: SAFC Commercial Organic Sales Performance

    21 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. 2013 SAFC COMMERCIAL ORGANIC SALES PERFORMANCE (Double Digit) (Mid Single Digit) Low Single Digit Mid Single Digit (High Single Digit) Double Digit (Low Single Digit) High Single Digit Q1-13 Q2-13 Q3-13 LIFE S

  22. Slide 22: Long-Term Organic Sales Growth

    Slide 22: Long-Term Organic Sales Growth

    22 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. LONG-TERM ORGANIC SALES GROWTH ORGANIC SALES GR OW TH RESEARCH Low–Mid Single Digit Mid–High Single Digit Mid–High Single Digit APPLIED COMMERCIAL OVERALL ≥ ~Mid Single Digit

  23. Slide 23: Sigma-Aldrich Outlook to Increasing Shareholder Value

    Slide 23: Sigma-Aldrich Outlook to Increasing Shareholder Value

    23 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. SIGMA-ALDRICH OUTLOOK TO INCREASING SHAREHOLDER VALUE ORGANIC SALES GROWTH ≥ ~Mid Single Digit MARGIN EXPANSION OF CORE BUSINESS ~50 bps per Year ASSET MANAGEMENT M&A SHAREHOLDER VALUE HIGH ROIC HIGH FREE CASH

  24. Slide 24: Levers to Expand Margins

    Slide 24: Levers to Expand Margins

    24 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. ORGANIC SALES GROWTH ≥ ~MID SINGLE DIGITS SG&A LEVERAGE GROSS MARGIN EXPANSION New Global Supply Chain organization Manufacturing footprint Logistics and distribution Productivity and quality improvements Expen

  25. Slide 25: 2013: Another Year of Solid Cash Flow Growth

    Slide 25: 2013: Another Year of Solid Cash Flow Growth

    25 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. 2013: ANOTHER YEAR OF SOLID CASH FLOW GROWTH ON TRACK TO EXCEED $450M FREE CASH FLOW TOTAL DEBT 9/30/13 $414M TOTAL CASH 9/30/13 $688M ROIC 20% 9/30/13

  26. Slide 26: Uses of Cash

    Slide 26: Uses of Cash

    26 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. USES OF CASH INCREASING EPS AND DIVIDENDS FOR 38 CONSECUTIVE YEARS INVESTED CAPITAL EXPENDITURES REPURCHASED OF STOCK $1.5B$940M IN DIVIDENDS $700M DISTRIBUTED TO ACQUIRE 14 COMPANIES $1.2B INVESTED SINCE 2004:

  27. Slide 27: Organic and Inorganic Investments Increased Shareholder Value

    Slide 27: Organic and Inorganic Investments Increased Shareholder Value

    27 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reser ved. ORGANIC AND INORGANIC INVESTMENTS INCREASED SHAREHOLDER VALUE $90 $80 $70 $60 $50 $40 $30 $20 $10 $0 $100 2004 2006 2008 2010 2004 Tetrionics, Ultraf_ine Acquired 2005 Proligo Group, JRH Biosciences Acquired 2

  28. Slide 28: Sigma-Aldrich: A World-Class Organization

    Slide 28: Sigma-Aldrich: A World-Class Organization

    28 | J.P. MORGAN HEALTHCARE CONFERENCE © 2014 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH A WORLD-CLASS ORGANIZATION Well-positioned for the future Exceptional SCIENTIFIC KNOWLEDGE Superior QUALITY and COMPLIANCE First-Class Customer SERVICE Extensive SELECTION of Products and Services

Source: SEC EDGAR · 8-K filed Jan 13, 2014

More decks from Sigma-Aldrich Corp